Investor Relations
Dyax is a fully integrated biopharmaceutical company focused on discovering, developing and commercializing novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. We utilize our proprietary drug discovery technology, phage display, to identify antibody, small protein and peptide compounds for clinical development. Dyax also leverages this technology broadly with over 70 revenue generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents. Click here to learn more.
More »Stock Quote
| DYAX (Common Stock) | |
|---|---|
| Exchange | NASDAQ (US Dollars) |
| Price | $1.61 |
| Change (%) |
 0.01 (0.63)% |
| Volume | 113,100 |
| Data as of May 16, 2012 4:00 PM ET Delayed at least 20 minutes. Provided by eSignal. Refresh Quote |
|
More »Recent Releases
More »Calendar of Events
| Details on upcoming events are not yet available. |
More » Event Archives
|
|
Deutsche Bank Securities, Inc. 37th Annual Health Care Conference |
|
|
Dyax Corp. 1Q 2012 Earnings Call |
|
|
11th Annual Needham Healthcare Conference |
|
|
Cowen and Company 32nd Annual Health Care Conference |
Featured Financial Reports
| Filing Date | Title | Type | Size | |
|---|---|---|---|---|
| May 2, 2012 | 10-Q |
|
569.8 KB | |
| Apr 12, 2012 | 2011 Annual Report |
|
7.2 MB | |
Briefcase
Email Alerts
IR Contacts
RSS Feeds
Mobile Investor